Inhibrx Biosciences announced it will present clinical trial data for its novel biologic therapies at several upcoming oncology conferences in late 2026, including ESMO in Spain and MSTS in the US. Key presentations will cover phase 2/3 and phase 2 studies of their drug candidates ordastobart (INBRX-106) and ozekibart (INBRX-109) targeting head and neck cancer and chondrosarcoma. These presentations highlight Inhibrx's progress in developing innovative treatments using proprietary protein engineering platforms. Investors can access the presentations via the company's website during the events.
Inhibrx Biosciences clinical trial presentations are upcoming, while Pluang data shows a challenging day for the US health sector. For readers following health stocks, here is Pluang's market snapshot as of Oct 14, 2026 03:02 WIB: out of 128 priced health-sector US stocks, 28 rose and 100 fell. Notable movers include VRTX at USD 485.08 with a 4.32% decline, RXRX at USD 3.84 down 4.24%, and NBIX at USD 135.50 down 4.15%.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
